GPCR Therapeutics Demonstrates Clinical Improvement in Mobilization of Hematopoietic Stem Cells Using GPC-100/Burixafor in Clinical Pharmacology in Drug Development
Seoul, Korea, & Redwood City, California, 15 August 2023 – GPCR Therapeutics, Inc., a clinical stage, international biopharmaceutical company with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors (GPCR) pairs, announced today publication of their paper in Clinical Pharmacology in Drug Development (1), in collaboration with Taiwan’s TaiGen Biotechnology Co. Ltd. The paper is entitled, “Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC-100), a Novel C-X-C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects.” The results demonstrate that the company’s lead small molecule asset, GPC-100/burixafor, is generally safe and well tolerated. PK profile and marked increase of peripheral CD34+ cells after GPC-100 administration support further clinical development of GPC-100 for mobilization of hematopoietic stem/progenitor cells.
